Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Cabozantinib in HIV Patients With Advanced Solid Tumors
NCT04514484Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and cabozantinib in solid tumor and Kaposi sarcoma (KS), sponsored by National Cancer Institute. Primary endpoint: Incidence of Dose Limiting Toxicities at 28 days. Started Nov 2021; status: active, not recruiting.
02
Drugs
nivolumabcabozantinib
03
Conditions
solid tumorKaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT04514484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514484.